98%
921
2 minutes
20
Recent studies suggest that autophagy is highly involved in insulin resistance (IR). Inhibition of the PI3K/AKT/mTOR signaling pathway induces autophagy activation. Additionally, depletion of LRP6 has been shown to increase insulin sensitivity but its mechanism is still not clear. We hypothesized that LRP6 contributes to IR by regulating mTOR mediated autophagy through GSK3β in hepatocytes. LO2 hepatocytes were treated with palmitate (PA) and insulin to induced IR. Levels of LRP6 mRNA and protein expression were measured by real time-PCR and western blot analysis. LRP6 knock down was achieved by adenovirus mediated Si-LRP6 expression and its roles in IR, glucose, GSK3β, mTOR signaling, and autophagy were explored. Finally, GSK3β was overexpressed and its involvement in autophagy and IR was examined. We found that PA treatment led to a reduced glucose uptake and IR in hepatocytes, which was accompanied by an upregulation of LRP6 expression. Knocking down of LRP6 enhanced glucose uptake and insulin sensitivity in PA treated cells, probably through increasing GSK3b activity. Overexpression of GSK3b mimicked LRP6 reduction by enhancing autophagy and ameliorating IR. Our study revealed a significant molecular mechanism connecting LRP6 to insulin sensitivity through GSK3β-mTOR mediated autophagy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379257 | PMC |
http://dx.doi.org/10.3389/fendo.2019.00073 | DOI Listing |
Nat Sci Sleep
September 2025
Department of Geriatrics, Tianjin Medical University General Hospital; Tianjin Key Laboratory of Elderly Health; Tianjin Geriatrics Institute, Tianjin, People's Republic of China.
Background: Sleep and frailty are established influencing factors for cardiometabolic diseases (CMDs). However, their joint effects on cardiometabolic multimorbidity (CMM) in older adults remain poorly understood. This study aimed to assess the joint effect of sleep health and frailty on CMD prevalence and severity, with an emphasis on subgroup-specific health risk profiles.
View Article and Find Full Text PDFDiabetes Metab Syndr Obes
September 2025
Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
Insulin therapy remains a cornerstone in the management of type 2 diabetes mellitus (T2DM), especially in patients experiencing progressive loss of pancreatic beta-cell function or those with inadequate glycemic control despite oral antidiabetic therapy. This review synthesized clinical outcomes from 44 peer-reviewed case reports published between 2019 and 2024, identified through systematic searches in PubMed and Scopus. The included cases involved 15 males and 29 females, with patient ages ranging from 11 to 91 years (mean 53 ± 20.
View Article and Find Full Text PDFExp Ther Med
November 2025
Department of Obstetrics and Gynecology, Affiliated Maternity and Child Health Care Hospital of Nantong University, Nantong, Jiangsu 226007, P.R. China.
Gestational diabetes mellitus (GDM), a type of diabetes mellitus occurring in pregnant women, increases the risk of birth trauma. Solute carrier family 2 member 4 (SLC2A4) polymorphism is notably associated with GDM susceptibility; however, the mechanism is unknown. In the present study, HTR-8/SVneo cells were treated with high glucose concentrations and transfected with SLC2A4 and Forkhead box O (FoxO)1 to investigate their roles in the insulin (INS) resistance of GDM trophoblast cells.
View Article and Find Full Text PDFFront Nutr
August 2025
Emergency Department, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang City, Guizhou Province, China.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a rising health issue linked to poor diet and gut microbiota dysbiosis. The Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet, high in polyphenols and anti-inflammatory nutrients, may help protect against MASLD. This study examined how adherence to the MIND diet relates to MASLD severity, focusing on hepatic steatosis, fibrosis, insulin resistance, inflammation, and gut microbiota diversity.
View Article and Find Full Text PDFClin Kidney J
September 2025
Department of Nephrology. University Clinical Hospital, INCLIVA, Valencia. RICORS Renal Instituto de salud Carlos III, Valencia. Spain.
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a major contributor to systemic metabolic dysfunction and is increasingly recognized as a risk enhancer for both cardiovascular disease (CVD) and chronic kidney disease (CKD). This review explores the complex interconnections between MASLD, CVD, and CKD, with emphasis on shared pathophysiological mechanisms and the clinical implications for risk assessment and management. We describe the crosstalk among the liver, heart, and kidneys, focusing on insulin resistance, chronic inflammation, and progressive fibrosis as key mediators.
View Article and Find Full Text PDF